Augusto GA, Cassola N, Dualib PM, et al. - Researchers sought to summarize the evidence from systematic reviews (SRs) of randomized controlled trials (RCTs) assessing the effectiveness and safety of SGLT2 inhibitors (SGLT2i) vs placebo or active comparators for type 2 diabetes mellitus. Between 2014 and 2021, six databases were searched. They involved forty-six SRs, comprising 175 RCTs and 136,096 candidates. "Possible benefit" was noted in relation to major cardiovascular events, all-cause mortality, and nonalcoholic fatty liver disease. SGLT2i displayed "clear evidence of no effect or equivalence" in relation to stroke and fractures. "Clear evidence of harm" was seen in relation to genital infections and ketoacidosis. SGLT2i have been shown to improve renal and cardiovascular outcomes (except for stroke), HbA1c, and weight.